Jane Street Group LLC trimmed its position in shares of Cybin Inc. (NYSE:CYBN - Free Report) by 84.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,003 shares of the company's stock after selling 129,272 shares during the quarter. Jane Street Group LLC owned approximately 0.12% of Cybin worth $204,000 as of its most recent SEC filing.
Separately, Sanctuary Advisors LLC purchased a new stake in shares of Cybin in the second quarter valued at approximately $36,000. Institutional investors own 17.94% of the company's stock.
Cybin Stock Performance
Shares of NYSE CYBN traded up $0.01 during trading on Monday, reaching $8.90. The stock had a trading volume of 168,239 shares, compared to its average volume of 211,834. The stock has a market capitalization of $177.93 million, a P/E ratio of -1.34 and a beta of 0.44. Cybin Inc. has a fifty-two week low of $6.50 and a fifty-two week high of $19.85. The stock has a 50-day moving average price of $10.13.
Wall Street Analysts Forecast Growth
Several equities research analysts have commented on CYBN shares. Canaccord Genuity Group cut their price objective on Cybin from $96.00 to $86.00 and set a "buy" rating for the company in a research note on Thursday, November 14th. HC Wainwright reaffirmed a "buy" rating and issued a $190.00 price target on shares of Cybin in a research note on Monday, November 18th.
View Our Latest Stock Report on CYBN
Cybin Company Profile
(
Free Report)
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.
Featured Articles
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
